NewAmsterdam Pharma Company N.V.
NAMSNASDAQHealthcare● Active
$30.95
$-0.57(-1.81%)
Market Cap$3.6B
P/E Ratio—
52W High$42.205
52W Low$17.63
NewAmsterdam Pharma Company N.V. (NAMS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NAMS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.40
Est. -$0.46 · +13.0%
Revenue
$0.00B
Est. $0.00B · +72.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
NAMS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.48 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.46 | -$0.40 | +13.0% | $0.00B | $0.00B | +72.0% |
| ▼ Q1 FY2026 | Feb 18, 2026 | -$0.43 | -$0.63 | -45.1% | $0.00B | $0.00B | -98.9% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.38 | -$0.41 | -7.9% | $0.00B | $0.00B | -85.5% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.52 | -$0.15 | +71.2% | $0.02B | $0.00B | +542.0% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.45 | -$0.49 | -8.9% | $0.00B | $0.00B | +121.1% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.48 | -$0.95 | -97.9% | $0.01B | $0.00B | +653.3% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.48 | -$0.18 | +62.5% | $0.03B | $0.00B | +1637.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.48
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.40
EPS Est.
-$0.46
EPS Surpr.
+13.0%
Revenue
$0.00B
Q1 FY2026
Feb 18, 2026Miss
EPS Actual
-$0.63
EPS Est.
-$0.43
EPS Surpr.
-45.1%
Revenue
$0.00B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.38
EPS Surpr.
-7.9%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.52
EPS Surpr.
+71.2%
Revenue
$0.02B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.49
EPS Est.
-$0.45
EPS Surpr.
-8.9%
Revenue
$0.00B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.95
EPS Est.
-$0.48
EPS Surpr.
-97.9%
Revenue
$0.01B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$0.48
EPS Surpr.
+62.5%
Revenue
$0.03B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.74 | $-0.47 | $-0.21 | 4 |
| Q3 FY2028 | $-0.85 | $-0.54 | $-0.24 | 6 |
| Q2 FY2028 | $-0.88 | $-0.56 | $-0.25 | 4 |
| Q1 FY2028 | $-0.93 | $-0.59 | $-0.26 | 4 |
| Q4 FY2027 | $0.02 | $0.04 | $0.07 | 3 |
| Q3 FY2027 | $-0.54 | $-0.34 | $-0.15 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.1B | 6 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 7 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +13.0% | $30.99 | $34.85 | +12.46% |
| ▼ Q1 FY2026 | Feb 18, 2026 | -45.1% | $35.24 | $35.76 | +1.48% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -7.9% | $36.53 | $38.13 | +4.38% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +71.2% | $21.73 | $23.62 | +8.70% |
| ▼ Q2 FY2025 | May 8, 2025 | -8.9% | $18.92 | $19.27 | +1.85% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -97.9% | $17.88 | $19.71 | +10.23% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +62.5% | $19.15 | $21.78 | +13.73% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +13.6% | $16.23 | $15.66 | -3.51% |
Q2 FY2026+12.46%
Report Date
May 7, 2026
EPS Beat/Miss
+13.0%
Price Before
$30.99
Price After
$34.85
Q1 FY2026+1.48%
Report Date
Feb 18, 2026
EPS Beat/Miss
-45.1%
Price Before
$35.24
Price After
$35.76
Q4 FY2025+4.38%
Report Date
Nov 5, 2025
EPS Beat/Miss
-7.9%
Price Before
$36.53
Price After
$38.13
Q3 FY2025+8.70%
Report Date
Aug 6, 2025
EPS Beat/Miss
+71.2%
Price Before
$21.73
Price After
$23.62
Q2 FY2025+1.85%
Report Date
May 8, 2025
EPS Beat/Miss
-8.9%
Price Before
$18.92
Price After
$19.27
Q1 FY2025+10.23%
Report Date
Feb 26, 2025
EPS Beat/Miss
-97.9%
Price Before
$17.88
Price After
$19.71
Q4 FY2024+13.73%
Report Date
Nov 6, 2024
EPS Beat/Miss
+62.5%
Price Before
$19.15
Price After
$21.78
Q3 FY2024-3.51%
Report Date
Aug 7, 2024
EPS Beat/Miss
+13.6%
Price Before
$16.23
Price After
$15.66
Avg Beat Reaction+7.85%
Avg Miss Reaction+4.48%
Beat Rate4 / 8 quarters
Largest Move+13.73% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NAMS ends December
NewAmsterdam Pharma Company N.V. (NAMS) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.40 — beating the analyst consensus of $-0.46 by +13.0%. The next NAMS earnings date is expected around September 1, 2026.
Each quarter, investors track NAMS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NAMS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NAMS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NAMS earnings · 5 questionsNewAmsterdam Pharma Company N.V.'s next earnings report is expected around September 1, 2026. NAMS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NAMS historically reports after market close (AMC).
NAMS earnings datewhen is NAMS earningsNAMS next earnings datewhen does NAMS report earningsNAMS earnings calendar
▸ Source: FMP · NewAmsterdam Pharma Company N.V. SEC filings · US GAAP · NewAmsterdam Pharma Company N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026